TREM1 anticorps

N° du produit ABIN2191849

Détail du produit anti-TREM1 anticorps

Antigène: TREM1 (Triggering Receptor Expressed On Myeloid Cells 1 (TREM1))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp TREM1 est non-conjugé

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunofluorescence (IF), Functional Studies (Func)

Stérilité: 0.2 μm filtered

Clone: L5-B8

Information d'application

Indications d'application: For immunohistology, flow cytometry and Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.

Restrictions: For Research Use only

Stockage

Buffer: PBS, containing 0.1 % bovine serum albumin.

Stock: 4 °C

Stockage commentaire: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Date de péremption: 12 months

Détails sur TREM1

Antigène: TREM1 (Triggering Receptor Expressed On Myeloid Cells 1 (TREM1))

Autre désignation: Triggering Receptor Expressed On Myeloid Cells 1 (TREM1 Produits)

Synonymes: anticorps TREM1, anticorps CD354, anticorps TREM-1, anticorps triggering receptor expressed on myeloid cells 1, anticorps TREM1, anticorps Trem1, anticorps LOC100349504

Sujet: The monoclonal antibody L5-B8 recognizes mouse triggering receptor expressed on myeloid cells-1 (TREM-1). TREM-1 is a 30 kDa monomeric transmembrane activating receptor. TREM-1 is a member of the immunoglobulin superfamily. TREM-1 is expressed at low levels in the early development of the hematopoietic system in the promonoistic stage, and at high levels on the surface of immune cells, including neutrophils, monocytes and macrofages. TREM-1 is synthesized as a 234 amino acid (aa) precursor with a signal peptide (16 aa), an extracellular domain (184 aa), a transmembrane domain (29 aa), and a short cytoplasmic domain (5 aa). The short intracellular domain associates with a signal- transduction molecule, DNAX-activation protein 12 (DAP12), triggering the secretion of inflammatory cytokines that amplify the host response to microbial agents. TREM-1 acts in synergy with Toll-like receptor signaling pathways in amplifying the inflammatory response. Platelets express a natural ligand for TREM-1. The expression of TREM-1 is greatly upregulated on phagocytic cells in the presence of bacteria and fungi. TREM-1 has a role in sepsis, inflammatory bowel disease (IBD) and multiple sclerosis. In contrast, TREM-1 is not upregulated in samples from patients with non-inefctious inflammatory conditions. During infections, receptor expression is modulated and soluble TREM-1 (sTREM-1, 17 kDa) is released. TREM-1 is shed from the membrane of activated phagocytes and can be found as sTREM-1 in body fluids like plasma and bronchoalveolar lavage fluid (BAL). Elavated levels of sTREM-1 have a accuracy and sensitivity in detecting microbial infections as underlying disease. Furthermore, sTREM-1 has been associated with non-infectious inflammatory conditions like major abdominal surgery, peptic ulcer disease and COPD. Aliases TREM-1, triggering receptor expressed on myeloid cells, TREM1 Immunogen Mouse TREM-1-human IgG-Fc fusion protein